U.S. advisers back DNA-based colon cancer test

(Reuters) - A colon cancer screening method that uses stool samples won the unanimous backing of a U.S. advisory panel on Thursday, paving the way for potential regulatory approval of the DNA test. A panel of outside experts to the Food and Drug Administration voted 10-0 to recommend approval of the Cologuard screening test made by Exact Sciences Corp. While a colonoscopy is considered the most accurate method of detecting colon cancer and polyps, many people avoid the test, which involves inserting a flexible tube into the colon. If Cologuard is approved by the FDA, patients who have a positive cancer finding with the test, which identifies abnormal cells shed in the stool, would then undergo a colonoscopy.



via Health News Headlines - Yahoo News http://ift.tt/OYQHPO